nodes	percent_of_prediction	percent_of_DWPC	metapath
Labetalol—Alopecia—Mechlorethamine—lymphatic system cancer	0.00861	0.00861	CcSEcCtD
Labetalol—Liver function test abnormal—Fludarabine—lymphatic system cancer	0.00843	0.00843	CcSEcCtD
Labetalol—Raised liver function tests—Methotrexate—lymphatic system cancer	0.00807	0.00807	CcSEcCtD
Labetalol—Loss of libido—Methotrexate—lymphatic system cancer	0.00807	0.00807	CcSEcCtD
Labetalol—Sweating increased—Fludarabine—lymphatic system cancer	0.00768	0.00768	CcSEcCtD
Labetalol—Angina pectoris—Fludarabine—lymphatic system cancer	0.00768	0.00768	CcSEcCtD
Labetalol—Sweating—Teniposide—lymphatic system cancer	0.00767	0.00767	CcSEcCtD
Labetalol—Vertigo—Mechlorethamine—lymphatic system cancer	0.00762	0.00762	CcSEcCtD
Labetalol—Disorientation—Bleomycin—lymphatic system cancer	0.00748	0.00748	CcSEcCtD
Labetalol—Dysuria—Fludarabine—lymphatic system cancer	0.00738	0.00738	CcSEcCtD
Labetalol—Blood urea increased—Mitoxantrone—lymphatic system cancer	0.00706	0.00706	CcSEcCtD
Labetalol—Anaphylactic shock—Mechlorethamine—lymphatic system cancer	0.00692	0.00692	CcSEcCtD
Labetalol—Flushing—Teniposide—lymphatic system cancer	0.00667	0.00667	CcSEcCtD
Labetalol—Epistaxis—Fludarabine—lymphatic system cancer	0.00663	0.00663	CcSEcCtD
Labetalol—Alopecia—Teniposide—lymphatic system cancer	0.00635	0.00635	CcSEcCtD
Labetalol—Hypoaesthesia—Fludarabine—lymphatic system cancer	0.00628	0.00628	CcSEcCtD
Labetalol—Amnesia—Carmustine—lymphatic system cancer	0.00622	0.00622	CcSEcCtD
Labetalol—Visual impairment—Fludarabine—lymphatic system cancer	0.00608	0.00608	CcSEcCtD
Labetalol—Bronchospasm—Bleomycin—lymphatic system cancer	0.00569	0.00569	CcSEcCtD
Labetalol—Anaphylactoid reaction—Mitoxantrone—lymphatic system cancer	0.00561	0.00561	CcSEcCtD
Labetalol—Alopecia—Fludarabine—lymphatic system cancer	0.00558	0.00558	CcSEcCtD
Labetalol—Cardiac failure—Mitoxantrone—lymphatic system cancer	0.00556	0.00556	CcSEcCtD
Labetalol—Hypertension—Teniposide—lymphatic system cancer	0.0054	0.0054	CcSEcCtD
Labetalol—Liver function test abnormal—Carmustine—lymphatic system cancer	0.00539	0.00539	CcSEcCtD
Labetalol—Urinary retention—Vincristine—lymphatic system cancer	0.0053	0.0053	CcSEcCtD
Labetalol—Confusional state—Teniposide—lymphatic system cancer	0.00515	0.00515	CcSEcCtD
Labetalol—Oedema—Teniposide—lymphatic system cancer	0.0051	0.0051	CcSEcCtD
Labetalol—Hypersensitivity—Mechlorethamine—lymphatic system cancer	0.0051	0.0051	CcSEcCtD
Labetalol—Ill-defined disorder—Fludarabine—lymphatic system cancer	0.0051	0.0051	CcSEcCtD
Labetalol—Abdominal pain upper—Mitoxantrone—lymphatic system cancer	0.00496	0.00496	CcSEcCtD
Labetalol—Malaise—Fludarabine—lymphatic system cancer	0.00496	0.00496	CcSEcCtD
Labetalol—Hyperhidrosis—Teniposide—lymphatic system cancer	0.00493	0.00493	CcSEcCtD
Labetalol—Pruritus—Mechlorethamine—lymphatic system cancer	0.0049	0.0049	CcSEcCtD
Labetalol—Hypotension—Teniposide—lymphatic system cancer	0.00477	0.00477	CcSEcCtD
Labetalol—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.00474	0.00474	CcSEcCtD
Labetalol—Discomfort—Fludarabine—lymphatic system cancer	0.00462	0.00462	CcSEcCtD
Labetalol—Hypoaesthesia—Bleomycin—lymphatic system cancer	0.00461	0.00461	CcSEcCtD
Labetalol—Sweating increased—Mitoxantrone—lymphatic system cancer	0.00457	0.00457	CcSEcCtD
Labetalol—Dyspnoea—Teniposide—lymphatic system cancer	0.00455	0.00455	CcSEcCtD
Labetalol—Confusional state—Fludarabine—lymphatic system cancer	0.00452	0.00452	CcSEcCtD
Labetalol—Dysuria—Vincristine—lymphatic system cancer	0.00451	0.00451	CcSEcCtD
Labetalol—Depression—Carmustine—lymphatic system cancer	0.00449	0.00449	CcSEcCtD
Labetalol—Anaphylactic shock—Fludarabine—lymphatic system cancer	0.00449	0.00449	CcSEcCtD
Labetalol—Oedema—Fludarabine—lymphatic system cancer	0.00449	0.00449	CcSEcCtD
Labetalol—Erectile dysfunction—Vincristine—lymphatic system cancer	0.00444	0.00444	CcSEcCtD
Labetalol—Vomiting—Mechlorethamine—lymphatic system cancer	0.0044	0.0044	CcSEcCtD
Labetalol—Rash—Mechlorethamine—lymphatic system cancer	0.00436	0.00436	CcSEcCtD
Labetalol—Dermatitis—Mechlorethamine—lymphatic system cancer	0.00436	0.00436	CcSEcCtD
Labetalol—Hyperhidrosis—Fludarabine—lymphatic system cancer	0.00434	0.00434	CcSEcCtD
Labetalol—Erectile dysfunction—Mitoxantrone—lymphatic system cancer	0.00432	0.00432	CcSEcCtD
Labetalol—Flushing—Bleomycin—lymphatic system cancer	0.0043	0.0043	CcSEcCtD
Labetalol—Depression—Vincristine—lymphatic system cancer	0.00428	0.00428	CcSEcCtD
Labetalol—Feeling abnormal—Teniposide—lymphatic system cancer	0.00421	0.00421	CcSEcCtD
Labetalol—Drowsiness—Mitoxantrone—lymphatic system cancer	0.00418	0.00418	CcSEcCtD
Labetalol—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.00417	0.00417	CcSEcCtD
Labetalol—Sweating—Vincristine—lymphatic system cancer	0.00412	0.00412	CcSEcCtD
Labetalol—Nausea—Mechlorethamine—lymphatic system cancer	0.00411	0.00411	CcSEcCtD
Labetalol—Alopecia—Bleomycin—lymphatic system cancer	0.00409	0.00409	CcSEcCtD
Labetalol—Jaundice—Mitoxantrone—lymphatic system cancer	0.00408	0.00408	CcSEcCtD
Labetalol—Urticaria—Teniposide—lymphatic system cancer	0.00405	0.00405	CcSEcCtD
Labetalol—Abdominal pain—Teniposide—lymphatic system cancer	0.00403	0.00403	CcSEcCtD
Labetalol—Body temperature increased—Teniposide—lymphatic system cancer	0.00403	0.00403	CcSEcCtD
Labetalol—Erythema—Bleomycin—lymphatic system cancer	0.00403	0.00403	CcSEcCtD
Labetalol—Paraesthesia—Fludarabine—lymphatic system cancer	0.00403	0.00403	CcSEcCtD
Labetalol—Hypoaesthesia—Carmustine—lymphatic system cancer	0.00402	0.00402	CcSEcCtD
Labetalol—Hallucination—Carmustine—lymphatic system cancer	0.00402	0.00402	CcSEcCtD
Labetalol—Sweating—Mitoxantrone—lymphatic system cancer	0.00401	0.00401	CcSEcCtD
Labetalol—Dyspnoea—Fludarabine—lymphatic system cancer	0.004	0.004	CcSEcCtD
Labetalol—Oedema peripheral—Carmustine—lymphatic system cancer	0.00398	0.00398	CcSEcCtD
Labetalol—Dyspepsia—Fludarabine—lymphatic system cancer	0.00395	0.00395	CcSEcCtD
Labetalol—Agranulocytosis—Mitoxantrone—lymphatic system cancer	0.00391	0.00391	CcSEcCtD
Labetalol—Visual impairment—Carmustine—lymphatic system cancer	0.00389	0.00389	CcSEcCtD
Labetalol—Fatigue—Fludarabine—lymphatic system cancer	0.00387	0.00387	CcSEcCtD
Labetalol—Hallucination—Vincristine—lymphatic system cancer	0.00384	0.00384	CcSEcCtD
Labetalol—Hypoaesthesia—Vincristine—lymphatic system cancer	0.00384	0.00384	CcSEcCtD
Labetalol—Constipation—Fludarabine—lymphatic system cancer	0.00384	0.00384	CcSEcCtD
Labetalol—Pain—Fludarabine—lymphatic system cancer	0.00384	0.00384	CcSEcCtD
Labetalol—Bradycardia—Mitoxantrone—lymphatic system cancer	0.00382	0.00382	CcSEcCtD
Labetalol—Hypersensitivity—Teniposide—lymphatic system cancer	0.00376	0.00376	CcSEcCtD
Labetalol—Hepatitis—Mitoxantrone—lymphatic system cancer	0.00376	0.00376	CcSEcCtD
Labetalol—Flushing—Carmustine—lymphatic system cancer	0.00375	0.00375	CcSEcCtD
Labetalol—Ill-defined disorder—Bleomycin—lymphatic system cancer	0.00374	0.00374	CcSEcCtD
Labetalol—Feeling abnormal—Fludarabine—lymphatic system cancer	0.0037	0.0037	CcSEcCtD
Labetalol—Asthenia—Teniposide—lymphatic system cancer	0.00366	0.00366	CcSEcCtD
Labetalol—Malaise—Bleomycin—lymphatic system cancer	0.00363	0.00363	CcSEcCtD
Labetalol—Pruritus—Teniposide—lymphatic system cancer	0.00361	0.00361	CcSEcCtD
Labetalol—Alopecia—Carmustine—lymphatic system cancer	0.00357	0.00357	CcSEcCtD
Labetalol—Body temperature increased—Fludarabine—lymphatic system cancer	0.00355	0.00355	CcSEcCtD
Labetalol—Mental disorder—Carmustine—lymphatic system cancer	0.00354	0.00354	CcSEcCtD
Labetalol—Erythema—Carmustine—lymphatic system cancer	0.00352	0.00352	CcSEcCtD
Labetalol—Diarrhoea—Teniposide—lymphatic system cancer	0.00349	0.00349	CcSEcCtD
Labetalol—Alopecia—Vincristine—lymphatic system cancer	0.00341	0.00341	CcSEcCtD
Labetalol—Discomfort—Bleomycin—lymphatic system cancer	0.00339	0.00339	CcSEcCtD
Labetalol—Mental disorder—Vincristine—lymphatic system cancer	0.00338	0.00338	CcSEcCtD
Labetalol—Alopecia—Mitoxantrone—lymphatic system cancer	0.00332	0.00332	CcSEcCtD
Labetalol—Confusional state—Bleomycin—lymphatic system cancer	0.00332	0.00332	CcSEcCtD
Labetalol—Vision blurred—Carmustine—lymphatic system cancer	0.00332	0.00332	CcSEcCtD
Labetalol—Hypersensitivity—Fludarabine—lymphatic system cancer	0.0033	0.0033	CcSEcCtD
Labetalol—Tremor—Carmustine—lymphatic system cancer	0.0033	0.0033	CcSEcCtD
Labetalol—Oedema—Bleomycin—lymphatic system cancer	0.00329	0.00329	CcSEcCtD
Labetalol—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.00329	0.00329	CcSEcCtD
Labetalol—Erythema—Mitoxantrone—lymphatic system cancer	0.00327	0.00327	CcSEcCtD
Labetalol—Vomiting—Teniposide—lymphatic system cancer	0.00325	0.00325	CcSEcCtD
Labetalol—Asthenia—Fludarabine—lymphatic system cancer	0.00322	0.00322	CcSEcCtD
Labetalol—Rash—Teniposide—lymphatic system cancer	0.00322	0.00322	CcSEcCtD
Labetalol—Dermatitis—Teniposide—lymphatic system cancer	0.00322	0.00322	CcSEcCtD
Labetalol—Headache—Teniposide—lymphatic system cancer	0.0032	0.0032	CcSEcCtD
Labetalol—Pruritus—Fludarabine—lymphatic system cancer	0.00317	0.00317	CcSEcCtD
Labetalol—Vision blurred—Mitoxantrone—lymphatic system cancer	0.00308	0.00308	CcSEcCtD
Labetalol—Hypotension—Bleomycin—lymphatic system cancer	0.00307	0.00307	CcSEcCtD
Labetalol—Diarrhoea—Fludarabine—lymphatic system cancer	0.00307	0.00307	CcSEcCtD
Labetalol—Hypertension—Carmustine—lymphatic system cancer	0.00304	0.00304	CcSEcCtD
Labetalol—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.00303	0.00303	CcSEcCtD
Labetalol—Nausea—Teniposide—lymphatic system cancer	0.00303	0.00303	CcSEcCtD
Labetalol—Vertigo—Vincristine—lymphatic system cancer	0.00302	0.00302	CcSEcCtD
Labetalol—Paraesthesia—Bleomycin—lymphatic system cancer	0.00295	0.00295	CcSEcCtD
Labetalol—Malaise—Mitoxantrone—lymphatic system cancer	0.00295	0.00295	CcSEcCtD
Labetalol—Dyspnoea—Bleomycin—lymphatic system cancer	0.00293	0.00293	CcSEcCtD
Labetalol—Hypertension—Vincristine—lymphatic system cancer	0.0029	0.0029	CcSEcCtD
Labetalol—Confusional state—Carmustine—lymphatic system cancer	0.00289	0.00289	CcSEcCtD
Labetalol—Oedema—Carmustine—lymphatic system cancer	0.00287	0.00287	CcSEcCtD
Labetalol—Vomiting—Fludarabine—lymphatic system cancer	0.00285	0.00285	CcSEcCtD
Labetalol—Rash—Fludarabine—lymphatic system cancer	0.00283	0.00283	CcSEcCtD
Labetalol—Dermatitis—Fludarabine—lymphatic system cancer	0.00283	0.00283	CcSEcCtD
Labetalol—Hypertension—Mitoxantrone—lymphatic system cancer	0.00282	0.00282	CcSEcCtD
Labetalol—Pain—Bleomycin—lymphatic system cancer	0.00281	0.00281	CcSEcCtD
Labetalol—Headache—Fludarabine—lymphatic system cancer	0.00281	0.00281	CcSEcCtD
Labetalol—Anaphylactoid reaction—Methotrexate—lymphatic system cancer	0.0028	0.0028	CcSEcCtD
Labetalol—Lethargy—Methotrexate—lymphatic system cancer	0.00276	0.00276	CcSEcCtD
Labetalol—Discomfort—Mitoxantrone—lymphatic system cancer	0.00275	0.00275	CcSEcCtD
Labetalol—Anaphylactic shock—Vincristine—lymphatic system cancer	0.00274	0.00274	CcSEcCtD
Labetalol—Oedema—Vincristine—lymphatic system cancer	0.00274	0.00274	CcSEcCtD
Labetalol—Feeling abnormal—Bleomycin—lymphatic system cancer	0.00271	0.00271	CcSEcCtD
Labetalol—Confusional state—Mitoxantrone—lymphatic system cancer	0.00269	0.00269	CcSEcCtD
Labetalol—Hypotension—Carmustine—lymphatic system cancer	0.00268	0.00268	CcSEcCtD
Labetalol—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.00267	0.00267	CcSEcCtD
Labetalol—Oedema—Mitoxantrone—lymphatic system cancer	0.00267	0.00267	CcSEcCtD
Labetalol—Nausea—Fludarabine—lymphatic system cancer	0.00266	0.00266	CcSEcCtD
Labetalol—Hyperhidrosis—Vincristine—lymphatic system cancer	0.00265	0.00265	CcSEcCtD
Labetalol—Shock—Mitoxantrone—lymphatic system cancer	0.00263	0.00263	CcSEcCtD
Labetalol—Urticaria—Bleomycin—lymphatic system cancer	0.00261	0.00261	CcSEcCtD
Labetalol—Body temperature increased—Bleomycin—lymphatic system cancer	0.0026	0.0026	CcSEcCtD
Labetalol—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.00258	0.00258	CcSEcCtD
Labetalol—Paraesthesia—Carmustine—lymphatic system cancer	0.00258	0.00258	CcSEcCtD
Labetalol—Mood swings—Methotrexate—lymphatic system cancer	0.00256	0.00256	CcSEcCtD
Labetalol—Hypotension—Vincristine—lymphatic system cancer	0.00256	0.00256	CcSEcCtD
Labetalol—Dyspnoea—Carmustine—lymphatic system cancer	0.00256	0.00256	CcSEcCtD
Labetalol—Somnolence—Carmustine—lymphatic system cancer	0.00255	0.00255	CcSEcCtD
Labetalol—Liver function test abnormal—Methotrexate—lymphatic system cancer	0.0025	0.0025	CcSEcCtD
Labetalol—Hypotension—Mitoxantrone—lymphatic system cancer	0.00249	0.00249	CcSEcCtD
Labetalol—Paraesthesia—Vincristine—lymphatic system cancer	0.00246	0.00246	CcSEcCtD
Labetalol—Pain—Carmustine—lymphatic system cancer	0.00245	0.00245	CcSEcCtD
Labetalol—Constipation—Carmustine—lymphatic system cancer	0.00245	0.00245	CcSEcCtD
Labetalol—Hypersensitivity—Bleomycin—lymphatic system cancer	0.00242	0.00242	CcSEcCtD
Labetalol—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.0024	0.0024	CcSEcCtD
Labetalol—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.00238	0.00238	CcSEcCtD
Labetalol—Somnolence—Mitoxantrone—lymphatic system cancer	0.00237	0.00237	CcSEcCtD
Labetalol—Feeling abnormal—Carmustine—lymphatic system cancer	0.00237	0.00237	CcSEcCtD
Labetalol—Fatigue—Vincristine—lymphatic system cancer	0.00236	0.00236	CcSEcCtD
Labetalol—Asthenia—Bleomycin—lymphatic system cancer	0.00236	0.00236	CcSEcCtD
Labetalol—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.00235	0.00235	CcSEcCtD
Labetalol—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.00235	0.00235	CcSEcCtD
Labetalol—Pain—Vincristine—lymphatic system cancer	0.00234	0.00234	CcSEcCtD
Labetalol—Constipation—Vincristine—lymphatic system cancer	0.00234	0.00234	CcSEcCtD
Labetalol—Pruritus—Bleomycin—lymphatic system cancer	0.00233	0.00233	CcSEcCtD
Labetalol—Fatigue—Mitoxantrone—lymphatic system cancer	0.0023	0.0023	CcSEcCtD
Labetalol—Constipation—Mitoxantrone—lymphatic system cancer	0.00228	0.00228	CcSEcCtD
Labetalol—Pain—Mitoxantrone—lymphatic system cancer	0.00228	0.00228	CcSEcCtD
Labetalol—Body temperature increased—Carmustine—lymphatic system cancer	0.00227	0.00227	CcSEcCtD
Labetalol—Abdominal pain—Carmustine—lymphatic system cancer	0.00227	0.00227	CcSEcCtD
Labetalol—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.00224	0.00224	CcSEcCtD
Labetalol—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.0022	0.0022	CcSEcCtD
Labetalol—Dysuria—Methotrexate—lymphatic system cancer	0.00219	0.00219	CcSEcCtD
Labetalol—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.00218	0.00218	CcSEcCtD
Labetalol—Abdominal pain—Vincristine—lymphatic system cancer	0.00217	0.00217	CcSEcCtD
Labetalol—Body temperature increased—Vincristine—lymphatic system cancer	0.00217	0.00217	CcSEcCtD
Labetalol—Erectile dysfunction—Methotrexate—lymphatic system cancer	0.00215	0.00215	CcSEcCtD
Labetalol—Urticaria—Mitoxantrone—lymphatic system cancer	0.00212	0.00212	CcSEcCtD
Labetalol—Hypersensitivity—Carmustine—lymphatic system cancer	0.00212	0.00212	CcSEcCtD
Labetalol—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.00211	0.00211	CcSEcCtD
Labetalol—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.00211	0.00211	CcSEcCtD
Labetalol—Vomiting—Bleomycin—lymphatic system cancer	0.00209	0.00209	CcSEcCtD
Labetalol—Drowsiness—Methotrexate—lymphatic system cancer	0.00208	0.00208	CcSEcCtD
Labetalol—Depression—Methotrexate—lymphatic system cancer	0.00208	0.00208	CcSEcCtD
Labetalol—Rash—Bleomycin—lymphatic system cancer	0.00207	0.00207	CcSEcCtD
Labetalol—Dermatitis—Bleomycin—lymphatic system cancer	0.00207	0.00207	CcSEcCtD
Labetalol—Asthenia—Carmustine—lymphatic system cancer	0.00206	0.00206	CcSEcCtD
Labetalol—Hypersensitivity—Vincristine—lymphatic system cancer	0.00202	0.00202	CcSEcCtD
Labetalol—Sweating—Methotrexate—lymphatic system cancer	0.002	0.002	CcSEcCtD
Labetalol—Epistaxis—Methotrexate—lymphatic system cancer	0.00197	0.00197	CcSEcCtD
Labetalol—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.00197	0.00197	CcSEcCtD
Labetalol—Asthenia—Vincristine—lymphatic system cancer	0.00197	0.00197	CcSEcCtD
Labetalol—Diarrhoea—Carmustine—lymphatic system cancer	0.00196	0.00196	CcSEcCtD
Labetalol—Nausea—Bleomycin—lymphatic system cancer	0.00195	0.00195	CcSEcCtD
Labetalol—Agranulocytosis—Methotrexate—lymphatic system cancer	0.00195	0.00195	CcSEcCtD
Labetalol—Asthenia—Mitoxantrone—lymphatic system cancer	0.00191	0.00191	CcSEcCtD
Labetalol—Dizziness—Carmustine—lymphatic system cancer	0.0019	0.0019	CcSEcCtD
Labetalol—Diarrhoea—Vincristine—lymphatic system cancer	0.00188	0.00188	CcSEcCtD
Labetalol—Hepatitis—Methotrexate—lymphatic system cancer	0.00187	0.00187	CcSEcCtD
Labetalol—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.00183	0.00183	CcSEcCtD
Labetalol—Vomiting—Carmustine—lymphatic system cancer	0.00183	0.00183	CcSEcCtD
Labetalol—Dizziness—Vincristine—lymphatic system cancer	0.00181	0.00181	CcSEcCtD
Labetalol—Rash—Carmustine—lymphatic system cancer	0.00181	0.00181	CcSEcCtD
Labetalol—Dermatitis—Carmustine—lymphatic system cancer	0.00181	0.00181	CcSEcCtD
Labetalol—Visual impairment—Methotrexate—lymphatic system cancer	0.0018	0.0018	CcSEcCtD
Labetalol—Headache—Carmustine—lymphatic system cancer	0.0018	0.0018	CcSEcCtD
Labetalol—Vomiting—Vincristine—lymphatic system cancer	0.00174	0.00174	CcSEcCtD
Labetalol—Rash—Vincristine—lymphatic system cancer	0.00173	0.00173	CcSEcCtD
Labetalol—Dermatitis—Vincristine—lymphatic system cancer	0.00173	0.00173	CcSEcCtD
Labetalol—Headache—Vincristine—lymphatic system cancer	0.00172	0.00172	CcSEcCtD
Labetalol—Nausea—Carmustine—lymphatic system cancer	0.00171	0.00171	CcSEcCtD
Labetalol—Vomiting—Mitoxantrone—lymphatic system cancer	0.0017	0.0017	CcSEcCtD
Labetalol—Rash—Mitoxantrone—lymphatic system cancer	0.00168	0.00168	CcSEcCtD
Labetalol—Dermatitis—Mitoxantrone—lymphatic system cancer	0.00168	0.00168	CcSEcCtD
Labetalol—Headache—Mitoxantrone—lymphatic system cancer	0.00167	0.00167	CcSEcCtD
Labetalol—Alopecia—Methotrexate—lymphatic system cancer	0.00165	0.00165	CcSEcCtD
Labetalol—Mental disorder—Methotrexate—lymphatic system cancer	0.00164	0.00164	CcSEcCtD
Labetalol—Erythema—Methotrexate—lymphatic system cancer	0.00163	0.00163	CcSEcCtD
Labetalol—Nausea—Vincristine—lymphatic system cancer	0.00163	0.00163	CcSEcCtD
Labetalol—Nausea—Mitoxantrone—lymphatic system cancer	0.00159	0.00159	CcSEcCtD
Labetalol—Vision blurred—Methotrexate—lymphatic system cancer	0.00154	0.00154	CcSEcCtD
Labetalol—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.00151	0.00151	CcSEcCtD
Labetalol—Malaise—Methotrexate—lymphatic system cancer	0.00147	0.00147	CcSEcCtD
Labetalol—Vertigo—Methotrexate—lymphatic system cancer	0.00146	0.00146	CcSEcCtD
Labetalol—Discomfort—Methotrexate—lymphatic system cancer	0.00137	0.00137	CcSEcCtD
Labetalol—Confusional state—Methotrexate—lymphatic system cancer	0.00134	0.00134	CcSEcCtD
Labetalol—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.00133	0.00133	CcSEcCtD
Labetalol—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.00129	0.00129	CcSEcCtD
Labetalol—Hypotension—Methotrexate—lymphatic system cancer	0.00124	0.00124	CcSEcCtD
Labetalol—Paraesthesia—Methotrexate—lymphatic system cancer	0.00119	0.00119	CcSEcCtD
Labetalol—Dyspnoea—Methotrexate—lymphatic system cancer	0.00119	0.00119	CcSEcCtD
Labetalol—Somnolence—Methotrexate—lymphatic system cancer	0.00118	0.00118	CcSEcCtD
Labetalol—Dyspepsia—Methotrexate—lymphatic system cancer	0.00117	0.00117	CcSEcCtD
Labetalol—Fatigue—Methotrexate—lymphatic system cancer	0.00115	0.00115	CcSEcCtD
Labetalol—Pain—Methotrexate—lymphatic system cancer	0.00114	0.00114	CcSEcCtD
Labetalol—Feeling abnormal—Methotrexate—lymphatic system cancer	0.0011	0.0011	CcSEcCtD
Labetalol—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.00109	0.00109	CcSEcCtD
Labetalol—Urticaria—Methotrexate—lymphatic system cancer	0.00106	0.00106	CcSEcCtD
Labetalol—Abdominal pain—Methotrexate—lymphatic system cancer	0.00105	0.00105	CcSEcCtD
Labetalol—Body temperature increased—Methotrexate—lymphatic system cancer	0.00105	0.00105	CcSEcCtD
Labetalol—Hypersensitivity—Methotrexate—lymphatic system cancer	0.00098	0.00098	CcSEcCtD
Labetalol—Asthenia—Methotrexate—lymphatic system cancer	0.000954	0.000954	CcSEcCtD
Labetalol—Pruritus—Methotrexate—lymphatic system cancer	0.000941	0.000941	CcSEcCtD
Labetalol—Diarrhoea—Methotrexate—lymphatic system cancer	0.00091	0.00091	CcSEcCtD
Labetalol—Dizziness—Methotrexate—lymphatic system cancer	0.000879	0.000879	CcSEcCtD
Labetalol—Vomiting—Methotrexate—lymphatic system cancer	0.000845	0.000845	CcSEcCtD
Labetalol—Rash—Methotrexate—lymphatic system cancer	0.000838	0.000838	CcSEcCtD
Labetalol—Dermatitis—Methotrexate—lymphatic system cancer	0.000838	0.000838	CcSEcCtD
Labetalol—Headache—Methotrexate—lymphatic system cancer	0.000833	0.000833	CcSEcCtD
Labetalol—Nausea—Methotrexate—lymphatic system cancer	0.00079	0.00079	CcSEcCtD
